Non-inferiority and some clinical advantages over ordinary human insulin (fewer doses, increased flexibility, less hypoglycemia and improved cost-effectiveness) have been documented [2], but only a few studies have directly compared the clinical efficacy of various RAIs [3–6], and none have addressed long-term cardiovascular safety. This evidence concerns the gene INS and Hypoglycemia.